Cue Biopharma Q2 net loss $153M, revenue $7.9M, $50M PIPE

Cue Biopharma, Inc.

Q2 revenue $7.9M vs $3.0M YoY; net loss $153.1M vs $8.5M, driven by one-time charges.
R&D expenses $49.0M incl. $20M cash to Ascendant and $20M warrant fair value; G&A $46.6M incl. $23M integration and $19.7M stock comp.
Cash $17.4M at June 30; completed $50M private placement after quarter-end.
Submitted IND to FDA for CUE-221 in food allergy; Phase 2 data in chronic spontaneous urticaria expected by end of Q3 2026.
Appointed Dr. Dominic Borie as CMO/Head of R&D and James M. Ahlers as CFO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.